Adicet Bio, Inc. 8K

Adicet Bio provided a development update highlighting completion of the planned analysis dataset for its prula-cel SLE trial, FDA IND clearance for ADI-212 in mCRPC, and forward timelines for its in vivo CAR-T pipeline.

On September 1, 2026, Adicet Bio, Inc. announced that it has completed the last patient visit for the planned Phase 1 safety and efficacy analysis of its allogeneic CAR-T candidate prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus with or without lupus nephritis, with topline results expected later in September 2026 and development of a potential registrational trial design underway following FDA interaction; the company also reported that the FDA cleared its IND for ADI-212 in August 2026 to treat metastatic castration-resistant prostate cancer with Phase 1 enrollment expected to begin in 4Q 2026, expanded prula-cel administration into the outpatient setting after FDA alignment, plans a clinical update in systemic sclerosis in 4Q 2026, and is advancing a next-generation in vivo CAR-T platform with its first candidate anticipated to enter clinical development in the second half of 2027.

Filing Facts

CIK

1720580

Ticker

-

Form

8K

Source Type

sec

Accession

0001720580-26-000054

Alert Tier

6